Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers

Gastrointestinal (GI) cancers, including colorectal cancer, pancreatic cancer, liver cancer and gastric cancer, are severe social burdens due to high incidence and mortality rates. Bromodomain and extra-terminal (BET) proteins are epigenetic readers consisting of four conserved members (BRD2, BRD3,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Hui-Yan, Du, Song-Tao, Li, Ya-Yun, Deng, Guang-Tong, Zeng, Fu-Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790409/
https://www.ncbi.nlm.nih.gov/pubmed/35116104
http://dx.doi.org/10.4251/wjgo.v14.i1.75
_version_ 1784639999007784960
author Sun, Hui-Yan
Du, Song-Tao
Li, Ya-Yun
Deng, Guang-Tong
Zeng, Fu-Rong
author_facet Sun, Hui-Yan
Du, Song-Tao
Li, Ya-Yun
Deng, Guang-Tong
Zeng, Fu-Rong
author_sort Sun, Hui-Yan
collection PubMed
description Gastrointestinal (GI) cancers, including colorectal cancer, pancreatic cancer, liver cancer and gastric cancer, are severe social burdens due to high incidence and mortality rates. Bromodomain and extra-terminal (BET) proteins are epigenetic readers consisting of four conserved members (BRD2, BRD3, BRD4 and BRDT). BET family perform pivotal roles in tumorigenesis through transcriptional regulation, thereby emerging as potential therapeutic targets. BET inhibitors, disrupting the interaction between BET proteins and acetylated lysines, have been reported to suppress tumor initiation and progression in most of GI cancers. In this review, we will demonstrate how BET proteins participate in the GI cancers progression and highlight the therapeutic potential of targeting BET proteins for GI cancers treatment.
format Online
Article
Text
id pubmed-8790409
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-87904092022-02-02 Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers Sun, Hui-Yan Du, Song-Tao Li, Ya-Yun Deng, Guang-Tong Zeng, Fu-Rong World J Gastrointest Oncol Review Gastrointestinal (GI) cancers, including colorectal cancer, pancreatic cancer, liver cancer and gastric cancer, are severe social burdens due to high incidence and mortality rates. Bromodomain and extra-terminal (BET) proteins are epigenetic readers consisting of four conserved members (BRD2, BRD3, BRD4 and BRDT). BET family perform pivotal roles in tumorigenesis through transcriptional regulation, thereby emerging as potential therapeutic targets. BET inhibitors, disrupting the interaction between BET proteins and acetylated lysines, have been reported to suppress tumor initiation and progression in most of GI cancers. In this review, we will demonstrate how BET proteins participate in the GI cancers progression and highlight the therapeutic potential of targeting BET proteins for GI cancers treatment. Baishideng Publishing Group Inc 2022-01-15 2022-01-15 /pmc/articles/PMC8790409/ /pubmed/35116104 http://dx.doi.org/10.4251/wjgo.v14.i1.75 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Review
Sun, Hui-Yan
Du, Song-Tao
Li, Ya-Yun
Deng, Guang-Tong
Zeng, Fu-Rong
Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers
title Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers
title_full Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers
title_fullStr Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers
title_full_unstemmed Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers
title_short Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers
title_sort bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790409/
https://www.ncbi.nlm.nih.gov/pubmed/35116104
http://dx.doi.org/10.4251/wjgo.v14.i1.75
work_keys_str_mv AT sunhuiyan bromodomainandextraterminalinhibitorsemergeaspotentialtherapeuticavenuesforgastrointestinalcancers
AT dusongtao bromodomainandextraterminalinhibitorsemergeaspotentialtherapeuticavenuesforgastrointestinalcancers
AT liyayun bromodomainandextraterminalinhibitorsemergeaspotentialtherapeuticavenuesforgastrointestinalcancers
AT dengguangtong bromodomainandextraterminalinhibitorsemergeaspotentialtherapeuticavenuesforgastrointestinalcancers
AT zengfurong bromodomainandextraterminalinhibitorsemergeaspotentialtherapeuticavenuesforgastrointestinalcancers

Ejemplares similares